Related Experiment Videos

[Cystinosis from childhood to adulthood]

M Broyer1

  • 1Service de néphrologie pédiatrique AP HP, Hôpital Necker Enfants Malades, Université René Descartes, Paris.

Nephrologie
|March 24, 2000
PubMed

Insights

Nephropathic cystinosis, a metabolic disorder causing cystine buildup, can be managed with early cysteamine treatment. This intervention delays kidney failure and growth issues, improving outcomes for affected children.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Context:

  • Nephropathic cystinosis is a rare inherited metabolic disorder.
  • Characterized by lysosomal cystine accumulation in multiple organs.
  • Leads to progressive kidney damage and failure in childhood.

Purpose:

  • To summarize the clinical presentation, diagnosis, and management of nephropathic cystinosis.
  • To highlight the impact of early cysteamine treatment on disease progression.
  • To discuss the genetic basis and diagnostic tools for cystinosis.

Summary:

  • Nephropathic cystinosis presents in infancy with failure to thrive and proximal tubulopathy.
  • Early cysteamine therapy significantly alters the disease course, preventing end-stage renal disease and growth failure.
  • Diagnosis relies on leukocyte cystine assay; prenatal diagnosis and genetic identification offer further insights.

Impact:

  • Early diagnosis and treatment are crucial for improving long-term outcomes in cystinosis.
  • Cysteamine therapy transforms the prognosis, mitigating severe complications.
  • Understanding the genetic defect provides a basis for improved diagnostics and potential future therapies.

Related Concept Videos